Choose your Region

Are you sure you want to proceed?

You will be leaving the Cook Medical website that you were viewing and going to a Cook Medical website for another region or country. Not all products are approved in all regulatory jurisdictions. The product information on these websites is intended only for licensed physicians and healthcare professionals.

Urology

By the numbers: Prostate cancer


We humans are fascinated with statistics. In all aspects of life—politics, sports, the economy, healthcare—the numbers we come across can tell us the good, and the bad, in any given situation. When it comes to cancer facts and figures, most of the numbers we come across reflect the negative aspects of this disease, and rightfully so. But there are also some figures that can offer hope.

bloggraphic_2015-10-14_104944Take prostate cancer, for example—a focus of ours this Movember. Other than skin cancer, prostate cancer is the most common cancer in men.1 And it is number one in terms of new cases in men, at around 28% of new cancer diagnoses for men.2 Dig a bit deeper and we read that 1 in 7 men will be diagnosed with prostate cancer during his lifetime.1 This year alone, there will be approximately 220,000 new cases of prostate cancer in the U.S.Those are certainly sobering statistics.

But it’s all about perspective. While prostate cancer is the most common cancer in American men, it doesn’t have the highest mortality rate. More than 2.9 million men who have been diagnosed with prostate cancer are still alive.1

A closer look at the survival rates for prostate cancer reveals an even better prognosis. According to cancer.org, for all stages of prostate cancer:

If you or someone you know has been diagnosed with prostate cancer, those survival statistics can be the light at the end of the tunnel. Finding the good among the bad is what keeps us going. It’s how we find the strength to fight.


1cancer.org/cancer/prostatecancer/index

2Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11-30.